Search Results - "Ferrante, Marc"

Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies.

Authors: Atreya, Raja Ferrante, Marc Panaccione, Remo et al.

Source: Journal of Crohn's & Colitis. Apr2025, Vol. 19 Issue 4, p1-11. 11p.

Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.

Authors: Ferrante, Marc Irving, Peter M Abreu, Maria T et al.

Source: Journal of Crohn's & Colitis. Mar2024, Vol. 18 Issue 3, p416-423. 8p.

Results of the Eighth Scientific Workshop of ECCO: Prevention and Treatment of Postoperative Recurrence in Patients With Crohn's Disease Undergoing an Ileocolonic Resection With Ileocolonic Anastomosis.

Authors: Ferrante, Marc Pouillon, Lieven Mañosa, Míriam et al.

Source: Journal of Crohn's & Colitis. Nov2023, Vol. 17 Issue 11, p1707-1722. 16p.

Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis.

Authors: Ferrante, Marc Peyrin-Biroulet, Laurent Arkkila, Perttu et al.

Source: Therapeutic Advances in Gastroenterology. 10/8/2025, Vol. 18, p1-12. 12p.

Optimizing the switch from escalated intravenous to subcutaneous infliximab: a population pharmacokinetics–pharmacodynamics study.

Authors: Wang, Zhigang Ferrante, Marc Vermeire, Séverine et al.

Source: Journal of Crohn's & Colitis. Aug2025, Vol. 19 Issue 8, p1-13. 13p.

Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study.

Authors: Ferrante, Marc Feagan, Brian G Panés, Julián et al.

Source: Journal of Crohn's & Colitis. Dec2021, Vol. 15 Issue 12, p2001-2010. 10p.

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.

Authors: Ferrante, Marc D'Haens, Geert Jairath, Vipul et al.

Source: Lancet. Dec2024, Vol. 404 Issue 10470, p2423-2436. 14p.

Efficacy of JAK inhibitors in Ulcerative Colitis.

Authors: Ferrante, Marc Sabino, João

Source: Journal of Crohn's & Colitis. 2020 Supplement, Vol. 14, pS737-S745. 9p.

Perioperative Use of Vedolizumab is not Associated with Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing Colectomy.

Authors: Ferrante, Marc de Buck van Overstraeten, Anthony Schils, Nikkie et al.

Source: Journal of Crohn's & Colitis. Nov2017, Vol. 11 Issue 11, p1353-1361. 9p.

Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis.

Authors: Noman, Maja Ferrante, Marc Bisschops, Raf et al.

Source: Journal of Crohn's & Colitis. Sep2017, Vol. 11 Issue 9, p1085-1089. 5p.

Serum extracellular RNAs as a noninvasive approach to differentiate inflammatory bowel disease subtypes: a proof-of-concept study.

Authors: Verstockt, Sare Sabino, João Ferrante, Marc et al.

Source: Journal of Crohn's & Colitis. May2025, Vol. 19 Issue 5, p1-7. 7p.

Editorial: risankizumab – ready to break ceilings?

Authors: Ferrante, Marc¹ (AUTHOR) marc.ferrante@uzleuven.be

Source: Alimentary Pharmacology & Therapeutics. Apr2023, Vol. 57 Issue 8, p909-910. 2p.

Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial.

Authors: Danese, Silvio Ferrante, Marc Feagan, Brian G. et al.

Source: American Journal of Gastroenterology (Lippincott Williams & Wilkins). Jan2023, Vol. 118 Issue 1, p138-147. 10p.

Failure of MMP-9 Antagonists in IBD: Demonstrating the Importance of Molecular Biology and Well-Controlled Early Phase Studies.

Authors: Bruyn, Magali de Ferrante, Marc

Source: Journal of Crohn's & Colitis. Sep2018, Vol. 12 Issue 9, p1011-1013. 3p.

Systematic versus Endoscopy-driven Treatment with Azathioprine to Prevent Postoperative Ileal Crohn's Disease Recurrence.

Authors: Ferrante, Marc Papamichael, Konstantinos Duricova, Dana et al.

Source: Journal of Crohn's & Colitis. Aug2015, Vol. 9 Issue 8, p617-624. 8p.

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.

Authors: Ferrante, Marc Panaccione, Remo Baert, Filip et al.

Source: Lancet. 5/28/2022, Vol. 339 Issue 10340, p2031-2046. 16p.

Subjects: Crohn's disease, Research, Clinical trials, Monoclonal antibodies, Evaluation research, Comparative studies, Randomized controlled trials, Blind experiment, Abdominal pain

Clustering of (auto)immune diseases with early-onset and complicated inflammatory bowel disease.

Authors: De Mesquita, Mirjam Bueno Ferrante, Marc Henckaerts, Liesbet et al.

Source: European Journal of Pediatrics. May2009, Vol. 168 Issue 5, p575-583. 9p. 3 Charts, 6 Graphs.

Needle or Drip?—Real-World Comparison of Intravenous to Subcutaneous Infliximab and Vedolizumab in the Management of Inflammatory Bowel Diseases.

Authors: Outtier, An Ferrante, Marc

Source: Digestive Diseases & Sciences. Jan2025, Vol. 70 Issue 1, p17-18. 2p.

Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era—getting nearer?

Authors: Verstockt, Bram Ferrante, Marc

Source: Alimentary Pharmacology & Therapeutics. Apr2020, Vol. 51 Issue 7, p737-738. 2p.

Ulcerative colitis disease severity affects the speed of symptom relief under filgotinib treatment: a post hoc analysis of the phase 2b/3 SELECTION study.

Authors: Saruta, Masayuki Danese, Silvio Takatori, Yoshie et al.

Source: Intestinal Research. Apr2026, Vol. 24 Issue 2, p329-340. 12p.